We Are Crinetics


Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.

Read the Latest


Crinetics Announces May 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals announces May 2023 inducement grants: the stock options were granted as inducements material to nine employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Crinetics Pharmaceuticals reported financial results and provided an update on first quarter 2023 clinical progress

Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1, 2)
Carcinoid Syndrome
Congenital Hyperinsulinism (Congenital HI)
Cushing's Disease, Congenital Adrenal Hyperplasia (CAH)
PTH Antagonist, Hyperparathyroidism
Undisclosed, Polycystic Kidney
TSH Antagonist, Graves' Disease, TED
Undisclosed (Multiple), Diabetes, Obesity
Targeted Radiotherapy Spin-out | Multiple Solid-Tumor Oncology
Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1, 2)
Carcinoid Syndrome
Congenital Hyperinsulinism (Congenital HI)
Cushing's Disease, Congenital Adrenal Hyperplasia (CAH)
PTH Antagonist, Hyperparathyroidism
Undisclosed, Polycystic Kidney
TSH Antagonist, Graves' Disease, TED
Undisclosed (Multiple), Diabetes, Obesity
Targeted Radiotherapy Spin-out | Multiple Solid-Tumor Oncology